Altamira Therapeutics, a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on April 10, 2024, will not undergo review. The SEC's communication, dated April 16, 2024, was addressed to Dr. Thomas Meyer, CEO of Altamira Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. Altamira Therapeutics was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. Doris Stacey Gama of the SEC is the point of contact for any further inquiries.

Altamira Therapeutics, a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on April 10, 2024, will not undergo review. The SEC's communication, dated April 16, 2024, was addressed to Dr. Thomas Meyer, CEO of Altamira Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. Altamira Therapeutics was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. Doris Stacey Gama of the SEC is the point of contact for any further inquiries.